Orchestra BioMed Holdings, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Orchestra BioMed Holdings, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Cash Locked Ratio: Money owed to suppliers is larger than money owed by customers plus stock: $17 per $100 of sales comes from others' credit, against $102 from others' credit three years earlier. Less money tied up than 96% of Healthcare companies in United States.
- Self-Funding Ratio: Over the last 3 years operating cash was negative while the company kept spending on investment (capex). Lower than 87% of Healthcare companies in United States.
- Growth Efficiency Ratio: Sales grew 848% in 3 years, but profit fell: $64 less profit per $100 of extra sales. Lower than 85% of Healthcare companies in United States.
Where $100 of sales goes
Latest year (Dec 2025). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
—Loss-making or profit too small
Over the last 3 years profit was a loss or under 2% of sales, so cash per 100 of profit is not meaningful.
Self-Funding Ratio
-170.1×Over the last 3 years operating cash was negative while the company kept spending on investment (capex).
Lower than 87% of Healthcare companies in United States.
Cash Locked Ratio
−$17Money owed to suppliers is larger than money owed by customers plus stock: $17 per $100 of sales comes from others' credit, against $102 from others' credit three years earlier.
Less money tied up than 96% of Healthcare companies in United States.
Growth quality
Steadiness Ratio
1/3 · 1/3Sales grew in 1 of the last 3 years; profit grew in 1 of 3.
Less steady than 70% of Healthcare companies in United States.
Growth Efficiency Ratio
−$64Sales grew 848% in 3 years, but profit fell: $64 less profit per $100 of extra sales.
Lower than 85% of Healthcare companies in United States.
Asset Productivity Ratio
+848% / +20%In 3 years sales changed by +848% while total assets changed by +20%. Sales grew faster than assets.
Balance-sheet strength
Debt Due Cover Ratio
-65.2×Operating cash was negative last year, while some debt falls due within a year.
Lower than 78% of Healthcare companies in United States.
Cash Cushion Ratio
+28%Cash, after subtracting all debt, equals 28% of its market value (net cash).
Higher than 67% of Healthcare companies in United States.
Tangible Assets Ratio
—Data incomplete
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (13)
Orchestra BioMed Holdings, Inc. made a loss over the last year. Orchestra BioMed Holdings, Inc. owes $0.83 for every $1 it owns. Orchestra BioMed Holdings, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossOrchestra BioMed Holdings, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
17.01The share price is 17.01 times Orchestra BioMed Holdings, Inc.'s book value per share, higher than 92% of Healthcare companies in United States.
Market cap
$329 MThe total market value of all of Orchestra BioMed Holdings, Inc.'s shares at today's price (share price × number of shares), smaller than 51% of Healthcare companies in United States. PosiCap size class: Mini Cap.
Net worth (book value)
$19 MWhat Orchestra BioMed Holdings, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$0.32Net worth divided by the number of shares. The share price of $5.47 is 17.0 times this, which is the P/B above.
Return on equity (ROE)
-397.3%Orchestra BioMed Holdings, Inc. lost 397.3% of its shareholders' money over the last year, lower than 92% of Healthcare companies in United States.
Owes vs Owns
0.83×Orchestra BioMed Holdings, Inc. owes $0.83 for every $1 it owns (high), higher than 79% of Healthcare companies in United States.
Dividend yield
NoneOrchestra BioMed Holdings, Inc. does not currently pay a dividend.
Revenue growth
+1169%Revenue rose 1169% in the year to Dec 2025, and grew 112% a year on average over 3 years.
Profit growth
LossOrchestra BioMed Holdings, Inc. made a loss in each of the last two years.
Profit margin
-157.4%Orchestra BioMed Holdings, Inc. lost $157 for every $100 of revenue.
Interest cover
Not coveredOrchestra BioMed Holdings, Inc.'s operating profit did not cover its interest costs in the year to Dec 2025.
Cash vs debt
Net cashOrchestra BioMed Holdings, Inc. held $91 M more cash than debt (net cash) at Dec 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Orchestra BioMed Holdings, Inc.: $329 M ÷ $19 M (30 Jun 2026) = 17.0.
What is Orchestra BioMed Holdings, Inc.'s return on equity?
Orchestra BioMed Holdings, Inc. lost 397.3% of its shareholders' money over the last year, lower than 92% of Healthcare companies in United States.
How much does Orchestra BioMed Holdings, Inc. owe compared with what it owns?
Orchestra BioMed Holdings, Inc. owes $0.83 for every $1 it owns (high), higher than 79% of Healthcare companies in United States.
Does Orchestra BioMed Holdings, Inc. pay a dividend?
No. Orchestra BioMed Holdings, Inc. does not currently pay a dividend.
Is Orchestra BioMed Holdings, Inc.'s revenue growing?
Revenue rose 1169% in the year to Dec 2025, and grew 112% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.